Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant

Pediatr Blood Cancer. 2014 Dec;61(12):2324-5. doi: 10.1002/pbc.25172. Epub 2014 Aug 17.

Authors

Bhakti Mehta¹, Kris Mahadeo, Re Zaw, Shinyi Tang, Neena Kapoor, Hisham Abdel-Azim

Affiliation

¹ Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California.

PMID: 25131654
DOI: 10.1002/pbc.25172

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / etiology
Antineoplastic Agents / therapeutic use*
Boronic Acids / therapeutic use*
Bortezomib
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Infant
Male
Prognosis
Pyrazines / therapeutic use*
Severe Combined Immunodeficiency / complications*
Severe Combined Immunodeficiency / therapy
Transplantation, Homologous

Substances

Antineoplastic Agents
Boronic Acids
Pyrazines
Bortezomib